Nemes Laszlo/iStock via Getty Images Arcellx’s Anito-cel: A Promising Contender in Multiple Myeloma Therapy Arcellx (NASDAQ:ACLX) is developing cell therapies for multiple myeloma [MM], acute myeloid leukemia, and myelodysplastic syndrome. Anito-cel (formerly CART-ddBCMA), the company's flagship product, is being developed in a Phase 2 pivotal trial for relapsed or refractory MM (rrMM). My last article on Arcellx was in September, a month after the FDA lifted the partial clinical hold (limits some trial asp ...